Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Benchtop Analyzer Promises 1-Hour UTI Detection and Antibiotic Sensitivity Indication

By LabMedica International staff writers
Posted on 12 Jan 2024

More than 400 million cases of urinary tract infections (UTIs) are reported every year across the world. More...

The gold standard for diagnosing UTIs and planning a treatment course depends on rapid dipstick tests and clinical diagnostic analysis. However, dipsticks have low specificity and can yield false positives, resulting in the overuse of antibiotics. Additionally, clinical tests have a lengthy turnaround time and offer 80% accuracy, resulting in physicians opting for the wrong course of treatment. Now, a benchtop analyzer with the ability to accurately identify the causative bug and the right antibiotic in under an hour could be a game changer for UTI diagnosis.

Astek Diagnostics (Baltimore, MD, USA) is developing the JIDDU benchtop analyzer to improve UTI diagnosis through rapid, one-hour turnaround times and an unprecedented 96% accuracy. Leveraging a novel method for antibiotic susceptibility testing (AST), JIDDU rapidly detects bacterial infections in urine samples, assesses infection severity, and delivers accurate AST results in an hour. The automated system comprises single-use sample cartridges, which separate the bacteria from urine, alongside a fluorescence analyzer that creates bacterial detection and an antibiotic susceptibility profile. The combined results ensure optimal treatment in significantly less time than the current methods.

By offering infection confirmation for UTIs and antibiotic sensitivity indication within one hour, JIDDU significantly improves diagnostic speed and accuracy, thus reducing patient complications and pain, as well as lowering healthcare costs. It marks a significant leap forward in patient care by enabling much more timely and accurate treatment as compared to the current standard of care. This can ultimately save lives, considering that 25% of sepsis cases are due to UTIs. Given that women contract UTIs up to 30 times more often than men, the JIDDU system would have major implications for women’s health. Astek Diagnostics is focused on going to market first with a urine-based test and expects to complete clinical trials by January 2025. In addition, the company aims to develop the JIDDU system into a multipurpose diagnostic platform with the ability to confirm bacterial infections and assess antibiotic sensitivity using four sample types: urine, CSF, effluent, and blood.

Related Links:
Astek Diagnostics


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.